{"id":28310,"date":"2015-06-01T09:12:53","date_gmt":"2015-06-01T09:12:53","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=28310"},"modified":"2015-06-11T09:08:03","modified_gmt":"2015-06-11T09:08:03","slug":"ema-approves-coformulated-atazanavircobicistat","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/28310","title":{"rendered":"EMA approves coformulated atazanavir\/cobicistat"},"content":{"rendered":"<p><strong>EMA press release<\/strong><\/p>\n<p><strong>On 21 May 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended approval in the EU for the combined formulation of atazanavir\/cobicistat (300 mg\/150 mg) film coated tablets.<\/strong><\/p>\n<p>The indication is for use with other antiretrovirals to treat HIV-1 in people without mutations associated with drug resistance to atazanavir.<\/p>\n<p>This combines the protease inhibitor atazanavir with the PK booster cobicistat in a single pill. The brand name is Evotaz and it is manufacted by Bristol-Myers Squibb.<\/p>\n<p>For full details see the summary of product characteristics (SmPC).<\/p>\n<p>Source:<\/p>\n<p>Committee for Medicinal Products for Human Use (CHMP). Evotaz Summary of opinion (initial authorisation). EMA\/CHMP\/277547\/2015. (21 May 2015).<br \/>\n<a href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003904\/smops\/Positive\/human_smop_000830.jsp&amp;mid=WC0b01ac058001d127\">http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003904\/smops\/Positive\/human_smop_000830.jsp&amp;mid=WC0b01ac058001d127<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EMA press release On 21 May 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended approval in the EU for the combined formulation of atazanavir\/cobicistat (300 mg\/150 mg) film coated tablets. The indication is for use with other &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-28310","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/28310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=28310"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/28310\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=28310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=28310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=28310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}